{"title":"Anti-Methicillin Resistant Staphylococcus aureus (MRSA) Activity of Pseudoalteromonas flavipulchra Isolated from Marine Waters of Batangas, Philippines","authors":"Arizaldo Enriquez Castro, Cristina C. Salibay","doi":"10.48048/WJST.2020.4789","DOIUrl":null,"url":null,"abstract":"The ocean boasts untapped novel producers of antibiotic substances in the form of unicellular organisms. One of the newest bioproducers of pharmacologically-significant substances studied for its potential against clinically-significant pathogens is the genus Pseudoalteromonas, a gammaproteobacterial group. This study is a preliminary report detailing the isolation of a Pseudoalteromonas flavipulchra species from Philippine marine waters. The isolate coded as PAM-003 was identified as 100 % similar to P. flavipulchra strain NCIMB2033 through 16s rRNA gene amplification and sequencing. PAM-003 was allowed to produce bioactives for 12 days. Afterwards, non-polar products were isolated from the base medium through membrane filtration, organic solvent extraction and rotary evaporation. The crude solution of bioactives injected in sterile discs was used for disc-diffusion assay against Methicillin Resistant Staphylococcus aureus (MRSA). Results indicate that PAM-003 demonstrated visually-appreciable zones of inhibition with a mean value of 8 mm. To further describe the antibacterial activity of the isolate, minimum inhibitory concentration (MIC) of the bacterial extract was determined through broth microdilution technique. Results indicate that PAM-003 demonstrated a MIC of 1000 µg/mL against MRSA. Additional investigation on the bioactivity of Philippine isolates from the genus Pseudoalteromonas isolated from highly diverse regions of the country is a considerable initiative for increasing the pipeline of new molecular entities for drug discovery.","PeriodicalId":255195,"journal":{"name":"Walailak Journal of Science and Technology (WJST)","volume":"42 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Walailak Journal of Science and Technology (WJST)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48048/WJST.2020.4789","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The ocean boasts untapped novel producers of antibiotic substances in the form of unicellular organisms. One of the newest bioproducers of pharmacologically-significant substances studied for its potential against clinically-significant pathogens is the genus Pseudoalteromonas, a gammaproteobacterial group. This study is a preliminary report detailing the isolation of a Pseudoalteromonas flavipulchra species from Philippine marine waters. The isolate coded as PAM-003 was identified as 100 % similar to P. flavipulchra strain NCIMB2033 through 16s rRNA gene amplification and sequencing. PAM-003 was allowed to produce bioactives for 12 days. Afterwards, non-polar products were isolated from the base medium through membrane filtration, organic solvent extraction and rotary evaporation. The crude solution of bioactives injected in sterile discs was used for disc-diffusion assay against Methicillin Resistant Staphylococcus aureus (MRSA). Results indicate that PAM-003 demonstrated visually-appreciable zones of inhibition with a mean value of 8 mm. To further describe the antibacterial activity of the isolate, minimum inhibitory concentration (MIC) of the bacterial extract was determined through broth microdilution technique. Results indicate that PAM-003 demonstrated a MIC of 1000 µg/mL against MRSA. Additional investigation on the bioactivity of Philippine isolates from the genus Pseudoalteromonas isolated from highly diverse regions of the country is a considerable initiative for increasing the pipeline of new molecular entities for drug discovery.